Compare GDHG & CTSO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GDHG | CTSO |
|---|---|---|
| Founded | 2008 | 1997 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Services-Misc. Amusement & Recreation | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 40.5M | 45.9M |
| IPO Year | 2023 | N/A |
| Metric | GDHG | CTSO |
|---|---|---|
| Price | $2.09 | $0.68 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $5.38 |
| AVG Volume (30 Days) | 11.6K | ★ 86.3K |
| Earning Date | 07-11-2025 | 03-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $15,288,195.00 | ★ $36,979,520.00 |
| Revenue This Year | N/A | $7.95 |
| Revenue Next Year | N/A | $8.80 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 23.89 |
| 52 Week Low | $1.82 | $0.60 |
| 52 Week High | $1,968.41 | $1.61 |
| Indicator | GDHG | CTSO |
|---|---|---|
| Relative Strength Index (RSI) | 34.93 | 49.88 |
| Support Level | $1.82 | $0.67 |
| Resistance Level | $2.27 | $0.74 |
| Average True Range (ATR) | 0.22 | 0.04 |
| MACD | 0.06 | 0.00 |
| Stochastic Oscillator | 25.64 | 44.11 |
Golden Heaven Group Holdings Ltd is an offshore holding company. Through the operating entities in China, it manages and operates six properties consisting of amusement parks, water parks, and complementary recreational facilities. The parks offer a broad selection of exhilarating and recreational experiences, including both thrilling and family-friendly rides, water attractions, gourmet festivals, circus performances, and high-tech facilities. The firm's revenue is generated from selling access to rides and attractions, charging fees for special event rentals, and collecting regular rental payments from commercial tenants. it opearts in the Cayman Islands, PRC, BVI, and HK.
CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales and Distributors/strategic partners in United States, Germany and Other Countries. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.